|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM33393492X |
| 003 |
DE-627 |
| 005 |
20231225222654.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||chi c |
| 024 |
7 |
|
|a 10.3760/cma.j.cn112140-20210827-00710
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1113.xml
|
| 035 |
|
|
|a (DE-627)NLM33393492X
|
| 035 |
|
|
|a (NLM)34856662
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Tan, A X
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical characteristics and risk factors of recurrent Kawasaki disease
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 06.12.2021
|
| 500 |
|
|
|a Date Revised 14.12.2021
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Objective: To summarize the clinical characteristics and explore the risk factors of recurrent Kawasaki disease. Methods: In this retrospective study, reviewed 41 cases with recurrent Kawasaki disease in Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University from January 2013 to January 2021. And another 123 children with Kawasaki disease who had no recurrence during at least 6 years of follow-up were assigned into control group. Furthermore, the risk factors of recurrence were derived by comparing the clinical characteristics of recurrent cases at their initial episodes with those of control cases by Chi-square test and the Mann-Whitney U test, followed by Logistic regression and receiver operating characteristic analysis. Results: There were 29 males and 12 females in 41 children with recurrent Kawasaki disease, 33 children (80%) suffered a recurrence within 2 years after the first episode and 8 children (20%) developed a recurrence after 2 years. Compared with the first episode, the second episode had lower white blood cell count (15.2 (12.8-18.8)×109 vs. 18.0 (14.9-23.4)×109/L, Z=-2.462, P=0.014) and rate of edema in extremities (54% (22/41) vs. 76% (31/41), χ2=4.321, P=0.038), shorter fever durations before intravenous immunoglobulin treatment (5.0 (5.0-6.0) vs. 6.0 (5.0-7.5) d, Z=-3.329, P=0.001) and higher levels of hemoglobin ((116±8) vs. (107±12)g/L, t=-4.124, P<0.05) and albumin((39±5) vs. (36±6) g/L, t=-3.009, P=0.004). Multivariate Logistic regression analysis showed that C-reaction protein>97.5 mg/L (OR=3.014, 95%CI 1.350-6.730, P=0.007), platelet >276 × 109/L (OR=4.099, 95%CI 1.309-12.838, P=0.015), intravenous immunoglobulin resistance (OR=9.239, 95%CI 1.178-72.477, P=0.034), Mycoplasma pneumoniae infection (OR=2.585, 95%CI 1.129-5.922, P=0.025) were independent risk factors for recurrent Kawasaki disease recurrence.The predictive model then was generated using these four risk factors. The receiver operating characteristic analysis showed that the area under curve was 0.732 (95%CI 0.647-0.817). When the cut-off was 0.241, the sensitivity and specificity were 63.4% and 70.7%, respectively. Conclusions: Children with Kawasaki disease should be followed up for at least 2 years after the first episode and should pay more attention to C-reactive protein. Children with Mycoplasma pneumoniae infection, intravenous immunoglobulin resistance, higher C-reactive protein and platelet at the first onset have a higher risk of recurrent Kawasaki disease
|
| 650 |
|
4 |
|a Journal Article
|
| 700 |
1 |
|
|a Tang, X M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhonghua er ke za zhi = Chinese journal of pediatrics
|d 1960
|g 59(2021), 12 vom: 02. Dez., Seite 1038-1042
|w (DE-627)NLM136249191
|x 0578-1310
|7 nnns
|
| 773 |
1 |
8 |
|g volume:59
|g year:2021
|g number:12
|g day:02
|g month:12
|g pages:1038-1042
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3760/cma.j.cn112140-20210827-00710
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_244
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_665
|
| 912 |
|
|
|a GBV_ILN_813
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 59
|j 2021
|e 12
|b 02
|c 12
|h 1038-1042
|